Latest Biotech News

Eli Lilly announced it will acquire Ajax Therapeutics for up to $2.3 billion, extending its M&A run into oncology. Ajax’s lead asset is a next-generation JAK2 inhibitor being evaluated in a Phase...

Sun Pharma agreed to buy Merck’s spinoff Organon in an all-cash transaction valued at $11.75 billion, aiming to expand its presence in women’s health and biosimilars. The deal is structured to...

Thermo Fisher Scientific announced it will sell its microbiology business to private equity firm Astorg for about $1.08 billion. The company said the transaction is expected to close in the second...

At AACR Annual Meeting 2026, investigators presented updated cohort results from the INFINITY phase 2 trial evaluating tremelimumab plus durvalumab as an organ-preserving option for resectable...

A report cited by industry stakeholders indicates British biotech equity funding showed early signs of recovery after a mid-2025 lull. In the first quarter of 2026, British biotechs reportedly...

At ESCMID, clinical microbiologists highlighted growing concerns that EU’s In Vitro Diagnostic Regulation (IVDR) may be constricting access to tests and slowing diagnostic development....

Veradermics reported success for its oral hair-loss candidate in a late-stage study, supporting the company’s transition as a public entity. In the trial, men with mild-to-moderate pattern hair...

Researchers at the University of California San Diego reported an AI-enhanced microscopy approach that captures real-time video inside living cells with higher clarity than conventional imaging....

Researchers have reported preclinical evidence that repurposed, clinically available drugs may improve outcomes in KMT2A::AFF1 positive infant B-cell precursor acute lymphoblastic leukemia...

A new study reports spatial predictors that may identify which patients with microsatellite stable (MSS) metastatic colorectal cancer could benefit from chemo-immunotherapy. By mapping treatment...

At AACR Annual Meeting 2026, investigators presented phase II INFINITY cohort results evaluating tremelimumab (Imjudo) plus durvalumab (Imfinzi) as an alternative to surgery for resectable gastric...

Researchers at VIB and VUB have introduced an orthotopic lung adenocarcinoma model paired with advanced single-cell sequencing to map the immune microenvironment with greater patient relevance....

Sun Pharma announced an all-cash acquisition of Organon for $11.75 billion as it expands its portfolio in women’s health and biosimilars. The deal, structured at $14 per share, brings Organon’s...

President Trump signed an executive order directing the FDA and other federal agencies to accelerate research and improve access to psychedelic drugs for serious mental illnesses. The order...

The World Health Organization prequalified Coartem Baby, the first and only antimalarial for babies, developed by Novartis in partnership with Medicines for Malaria Venture (MMV). The...

At SCAI 2026 Scientific Sessions & CAIC-ACCI Summit, the REACH trial presented performance data for a smart finger cuff algorithm aimed at detecting moderate-to-severe aortic stenosis. The report...

A newly published study in Engineering describes live-cell glycocalyx engineering strategies to advance adoptive cell therapies targeting B lymphoma. The work addresses persistent barriers in...

Researchers have identified the AURKA/PHB2 signaling axis as a driver of acquired resistance to KRAS G12C inhibitors in non-small cell lung cancer. The study, published in 2026, reports that this...

Sun Pharma has agreed to acquire Organon for $11.75 billion in an all-cash deal valued at $14 per share, expanding its footprint in women’s health and biosimilars. The transaction follows...

The World Health Organization has prequalified Coartem Baby, Novartis’ pediatric antimalarial combination developed with Medicines for Malaria Venture. The designation makes the product eligible...